The two binding constraints are (1) platform qualification/
design-in cycles that can both entrench Astera and slow/stop new ramps, and (2) supply-chain concentration (notably sole-source manufacturing partners) that can cap shipments regardless of demand. The most investor-relevant near-term risk remains valuation fragility into earnings: modest guide changes can
re-rate the stock even if the long-term story is intact.